Inozyme Pharma Merges with BioMarin for $270 Million

Inozyme Pharma ( (INZY) ) has shared an update.

On May 16, 2025, Inozyme Pharma entered into a merger agreement with BioMarin Pharmaceutical, where BioMarin will acquire Inozyme for $4.00 per share in an all-cash transaction totaling approximately $270 million. This acquisition aims to strengthen BioMarin’s enzyme therapies portfolio by adding INZ-701, a late-stage enzyme replacement therapy for ENPP1 Deficiency, with potential regulatory approval expected in 2027. The transaction has been approved by both companies’ boards and is anticipated to close in the third quarter of 2025, pending regulatory approval and other conditions.

The most recent analyst rating on (INZY) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inozyme Pharma stock, see the INZY Stock Forecast page.

Spark’s Take on INZY Stock

According to Spark, TipRanks’ AI Analyst, INZY is a Underperform.

Inozyme Pharma’s stock score reflects its early-stage biotechnology status with significant operational losses, zero revenue, and ongoing cash burn. Technical indicators show short-term momentum but highlight potential overbought conditions. The negative P/E ratio underscores the lack of profitability, and with no earnings data or corporate events provided, the score is primarily driven by weak financial performance.

To see Spark’s full report on INZY stock, click here.

More about Inozyme Pharma

Inozyme Pharma is a clinical-stage biopharmaceutical company based in Boston, focusing on developing innovative therapeutics targeting the PPi-Adenosine Pathway, crucial for bone health and blood vessel function. Their lead investigational therapy, INZ-701, is an enzyme replacement therapy for ENPP1 Deficiency and is in late-stage clinical development.

Average Trading Volume: 817,425

Technical Sentiment Signal: Sell

Current Market Cap: $87.16M

For a thorough assessment of INZY stock, go to TipRanks’ Stock Analysis page.